-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, July 5 News On July 1, the official website of the State Food and Drug Administration showed that Nanjing Chia Tai Tianqing’s aprepitant capsules were approved for production in generic 4 categories, which were deemed to have been reviewed
.
According to data from Meinnet.
com, in 2020, the combined sales of aprepitant capsules at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 200 million yuan, with Merck’s largest market share
.
.
According to data from Meinnet.
com, in 2020, the combined sales of aprepitant capsules at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 200 million yuan, with Merck’s largest market share
.
Data show that aprepitant is a neurokinin-1 (NK-1) receptor blocker, and its mechanism of action is to block the effect of substance P by binding to NK-1 receptors
.
The product has been unanimously recommended by authoritative guidelines in Europe and the United States such as the National Cancer Comprehensive Network Clinical Application Guidelines as the first-line drug and recommended drug for the prevention of nausea and vomiting caused by highly emetic anti- tumor chemotherapy
.
.
The product has been unanimously recommended by authoritative guidelines in Europe and the United States such as the National Cancer Comprehensive Network Clinical Application Guidelines as the first-line drug and recommended drug for the prevention of nausea and vomiting caused by highly emetic anti- tumor chemotherapy
.
Sales of Aprepitant Capsules in Entity Pharmacies in Chinese Cities (Unit: Ten Thousand Yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Meinenet, in 2020, the total sales of aprepitant capsules in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals exceed 200 million.
Yuan, of which, physical pharmacy terminals in Chinese cities increased by more than 15% year-on-year
.
Yuan, of which, physical pharmacy terminals in Chinese cities increased by more than 15% year-on-year
.
Source: One-click search on Mi Nei.
com
com
Prior to this, aprepitant capsule production enterprises only three, in July 2020, Qilu Pharmaceutical won the first copy; May this year, Chia Tai Pharmaceutical Group approved the listing
.
This time, Nanjing Chia Tai Tianqing was approved and became the third domestically-made enterprise
.
It is worth mentioning that these 3 domestic enterprises have been approved for the production of imitation 4 categories, which are regarded as over-reviewed
.
At present, the product has been approved by Sichuan Haisco Pharmaceuticals|Glenmark Pharmaceuticals Ltd.
as imported 5.
2 category
.
.
This time, Nanjing Chia Tai Tianqing was approved and became the third domestically-made enterprise
.
It is worth mentioning that these 3 domestic enterprises have been approved for the production of imitation 4 categories, which are regarded as over-reviewed
.
At present, the product has been approved by Sichuan Haisco Pharmaceuticals|Glenmark Pharmaceuticals Ltd.
as imported 5.
2 category
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network, July 5 News On July 1, the official website of the State Food and Drug Administration showed that Nanjing Chia Tai Tianqing’s aprepitant capsules were approved for production in generic 4 categories, which were deemed to have been reviewed
.
According to data from Meinnet.
com, in 2020, the combined sales of aprepitant capsules at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 200 million yuan, with Merck’s largest market share
.
.
According to data from Meinnet.
com, in 2020, the combined sales of aprepitant capsules at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 200 million yuan, with Merck’s largest market share
.
Data show that aprepitant is a neurokinin-1 (NK-1) receptor blocker, and its mechanism of action is to block the effect of substance P by binding to NK-1 receptors
.
The product has been unanimously recommended by authoritative guidelines in Europe and the United States such as the National Cancer Comprehensive Network Clinical Application Guidelines as the first-line drug and recommended drug for the prevention of nausea and vomiting caused by highly emetic anti- tumor chemotherapy
.
.
The product has been unanimously recommended by authoritative guidelines in Europe and the United States such as the National Cancer Comprehensive Network Clinical Application Guidelines as the first-line drug and recommended drug for the prevention of nausea and vomiting caused by highly emetic anti- tumor chemotherapy
.
Sales of Aprepitant Capsules in Entity Pharmacies in Chinese Cities (Unit: Ten Thousand Yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Meinenet, in 2020, the total sales of aprepitant capsules in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals exceed 200 million.
Yuan, of which, physical pharmacy terminals in Chinese cities increased by more than 15% year-on-year
.
Yuan, of which, physical pharmacy terminals in Chinese cities increased by more than 15% year-on-year
.
Source: One-click search on Mi Nei.
com
com
Prior to this, aprepitant capsule production enterprises only three, in July 2020, Qilu Pharmaceutical won the first copy; May this year, Chia Tai Pharmaceutical Group approved the listing
.
This time, Nanjing Chia Tai Tianqing was approved and became the third domestically-made enterprise
.
It is worth mentioning that these 3 domestic enterprises have been approved for the production of imitation 4 categories, which are regarded as over-reviewed
.
At present, the product has been approved by Sichuan Haisco Pharmaceuticals|Glenmark Pharmaceuticals Ltd.
as imported 5.
2 category
.
.
This time, Nanjing Chia Tai Tianqing was approved and became the third domestically-made enterprise
.
It is worth mentioning that these 3 domestic enterprises have been approved for the production of imitation 4 categories, which are regarded as over-reviewed
.
At present, the product has been approved by Sichuan Haisco Pharmaceuticals|Glenmark Pharmaceuticals Ltd.
as imported 5.
2 category
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network, July 5 News On July 1, the official website of the State Food and Drug Administration showed that Nanjing Chia Tai Tianqing’s aprepitant capsules were approved for production in generic 4 categories, which were deemed to have been reviewed
.
According to data from Meinnet.
com, in 2020, the combined sales of aprepitant capsules at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 200 million yuan, with Merck’s largest market share
.
.
According to data from Meinnet.
com, in 2020, the combined sales of aprepitant capsules at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 200 million yuan, with Merck’s largest market share
.
Data show that aprepitant is a neurokinin-1 (NK-1) receptor blocker, and its mechanism of action is to block the effect of substance P by binding to NK-1 receptors
.
The product has been unanimously recommended by authoritative guidelines in Europe and the United States such as the National Cancer Comprehensive Network Clinical Application Guidelines as the first-line drug and recommended drug for the prevention of nausea and vomiting caused by highly emetic anti- tumor chemotherapy
.
Tumor tumor tumor.
The product has been unanimously recommended by authoritative guidelines in Europe and the United States such as the National Cancer Comprehensive Network Clinical Application Guidelines as the first-line drug and recommended drug for the prevention of nausea and vomiting caused by highly emetic anti- tumor chemotherapy
.
Sales of Aprepitant Capsules in Entity Pharmacies in Chinese Cities (Unit: Ten Thousand Yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
According to data from Meinenet, in 2020, the total sales of aprepitant capsules in Chinese urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals and Chinese urban physical pharmacies terminals exceed 200 million.
Yuan, of which, physical pharmacy terminals in Chinese cities increased by more than 15% year-on-year
.
Hospital hospital hospital pharmacy pharmacy pharmacyYuan, of which, physical pharmacy terminals in Chinese cities increased by more than 15% year-on-year
.
Source: One-click search on Mi Nei.
com
com
Prior to this, aprepitant capsule production enterprises only three, in July 2020, Qilu Pharmaceutical won the first copy; May this year, Chia Tai Pharmaceutical Group approved the listing
.
This time, Nanjing Chia Tai Tianqing was approved and became the third domestically-made enterprise
.
It is worth mentioning that these 3 domestic enterprises have been approved for the production of imitation 4 categories, which are regarded as over-reviewed
.
At present, the product has been approved by Sichuan Haisco Pharmaceuticals|Glenmark Pharmaceuticals Ltd.
as imported 5.
2 category
.
Enterprise business enterprise.
This time, Nanjing Chia Tai Tianqing was approved and became the third domestically-made enterprise
.
It is worth mentioning that these 3 domestic enterprises have been approved for the production of imitation 4 categories, which are regarded as over-reviewed
.
At present, the product has been approved by Sichuan Haisco Pharmaceuticals|Glenmark Pharmaceuticals Ltd.
as imported 5.
2 category
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
